Supplementary Table 1. Search strategy.

|  |  |  |
| --- | --- | --- |
| PubMed/MEDLINE | Scopus | Web of sciences |
| (((("Tenofovir"[Mesh] OR Tenofovir[Title/Abstract]) OR Viread[Title/Abstract]) OR TDF[Title/Abstract]) AND ((("entecavir"[Supplementary Concept] OR entecavir[Title/Abstract]) OR Baraclude[Title/Abstract]) OR ETV[Title/Abstract])) AND ((((((((("Carcinoma, Hepatocellular"[Mesh] OR Liver Neoplasms[Title/Abstract]) OR hepatic neoplasm[Title/Abstract]) OR hepatocellular cancer[Title/Abstract]) OR hepatic cancer[Title/Abstract]) OR liver cancer[Title/Abstract]) OR liver cell carcinoma[Title/Abstract]) OR liver tumor[Title/Abstract]) OR hepatocellular carcinoma[Title/Abstract]) OR HCC[Title/Abstract]) | ( ( TITLE-ABS-KEY ( tenofovir ) OR TITLE-ABS-KEY ( viread ) OR TITLE-ABS-KEY ( tdf ) ) ) AND ( ( TITLE-ABS-KEY ( entecavir ) OR TITLE-ABS-KEY ( baraclude ) OR TITLE-ABS-KEY ( etv ) ) ) AND ( ( ( TITLE-ABS-KEY ( liver AND neoplasms ) OR TITLE-ABS-KEY ( hepatic AND neoplasm ) OR TITLE-ABS-KEY ( hepatocellular AND cancer ) OR TITLE-ABS-KEY ( hepatic AND cancer ) OR TITLE-ABS-KEY ( liver AND cancer ) OR TITLE-ABS-KEY ( liver AND cell AND carcinoma ) OR TITLE-ABS-KEY ( liver AND tumor ) OR TITLE-ABS-KEY ( hepatocellular AND carcinoma ) OR TITLE-ABS-KEY ( hcc ) ) ) ) | TS=("Liver Neoplasms" OR "hepatic neoplasm" OR "hepatocellular cancer" OR "hepatic cancer" OR "liver cancer" OR "liver cell carcinoma" OR "liver tumor" OR "hepatocellular carcinoma" OR HCC) AND TS=(Tenofovir OR Viread OR TDF) AND TS=(entecavir OR Baraclude OR ETV) |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary Table 2: Quality assessment of cohort study included in this study. | | | | | | | |
| **Quality assessment**  **criteria** | Yip, T. C. F. | Lee, S. W. | Kim, S. U. | Hsu, Y. C. | Choi, J. | Kim, B. G. | Tsai, M. C. |
| 2019 | 2019 | 2019 | 2019 | 2019 | 2018 | 2017 |
| Representativeness  of exposed cohort? | \* | \* | \* | \* | \* | \* | \* |
| Selection of the  non-exposed  cohort? | \* | \* | \* | \* | \* | \* | \* |
| Ascertainment of  exposure? | \* | \* | \* | \* | \* | \* | \* |
| Demonstration that  outcome of interest  was not present at  start of study? | \* | \* | \* | \* | \* | \* | \* |
| Study controls for  age/sex? | \* |  |  | \* | \* |  |  |
| Study controls for  at least 3 additional  risk factors? | \* |  |  | \* | \* |  |  |
| Assessment of  outcome? | \* | \* | \* | \* | \* | \* | \* |
| Was follow-up long  enough for outcome  to occur? | \* | \* | \* | \* | \* | \* | \* |
| Adequacy of  follow-up of  cohorts? | \* | \* | \* | \* | \* | \* | \* |
|  | 9 | 7 | 7 | 9 | 9 | 7 | 7 |

Supplementary Fig 1. Sensitivity analysis.

C:\Users\mah el\Desktop\team\vs hcc\9\sen.wmf